"The Report Global NASH
(Non-Alcoholics Steatohepatitis) Market: Trends, Opportunities and
Forecasts (2015-2030) (By Region, By Drugs - Off Label &
Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT
505 Market) provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
MarketResearchReports.biz
has recently announced the inclusion of a new market research report
to its huge database of research studies. The report provides an
in-depth analysis of the global non-alcoholic
steatohepatitis (NASH)
market based on a market overview, market drivers and restraints,
opportunities and challenges, market trends, product segmentation,
geographical segmentation, and the competitive analysis of the
market. The research report, titled “Global NASH (Non-Alcoholics
Steatohepatitis) Market: Trends, Opportunities And Forecasts
(2015-2030) (By Region, By Drugs - Off Label & Special Treatment
Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market)”,
will help industry experts, drug manufacturers, and major players
align their market-based strategies with the dominant trends in the
market.
Non-alcoholic
steatohepatitis (NASH) is a liver inflammation caused due to
accumulated fat in the liver. Building up of fat in the liver can be
seen in many cases and for most people it does not cause any problem
and symptoms. However, in some cases, the accumulated fat start
damaging cells in the liver. This condition can get worse and lead to
scarring of the liver, resulting in cirrhosis. NASH is similar to
liver disorders caused due to heavy and long-time alcohol
consumption, but can also occur in non-drinkers.
According
to the research study, the global market for non-alcoholic
steatohepatitis is projected to exhibit a 25.56% CAGR between 2020
and 2030 owing to the estimated product launches by the end of 2020.
In
the last five years, the significant prevalence of liver disorders,
coupled with the tremendous rise in obesity, is expected to boost the
global NASH market in the forecast period. NASH, at present, is an
enormous and untapped market, since it has no FDA-approved
therapeutics. The off-label products that are being used by NASH
patients include anti-diabetic medications, antioxidants, antihyper
lipidemics, and anti-obesity medications. In addition, the increasing
number of patients suffering from the condition is another factor
propelling the global NASH market throughout the forecast period. On
the other hand, the low prescription rates, low treatment seeking
rates, and low diagnosis rates are some of the major factors posing
significant challenges for the emerging players in the global NASH
market.
View Press Release @
http://www.marketresearchreports.biz/pressrelease/390
Furthermore,
the research report presents a detailed analysis of the global NASH
market on the basis of geography. Among all the regions, in 2014, the
U. S. accounted for a massive 50% of the global NASH market owing to
the high number of research initiatives conducted for NASH in this
region. The primary reason for this growth is the rising incidence of
obesity, diabetes, and the increasing number of people suffering from
fatty livers. The U.S. has recorded the highest number of cases of
NASH as well as other non-alcoholic fatty liver disorders.
The
research report further covers the competitive landscape of the
global NASH market including the company profile, contact
information, financial overview, business strategies, mergers and
acquisitions, SWOT analysis, and recent developments of major
companies. Some of the major players operating in the global NASH
market are Novo Nordisk, Galectin Therapeutics, Galmed
Pharmaceuticals, Gilead Sciences, and Genfit.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment